These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 8165983)

  • 1. Interval breast cancers in the Screening Mammography Program of British Columbia: analysis and classification.
    Burhenne HJ; Burhenne LW; Goldberg F; Hislop TG; Worth AJ; Rebbeck PM; Kan L
    AJR Am J Roentgenol; 1994 May; 162(5):1067-71; discussion 1072-5. PubMed ID: 8165983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival.
    Porter GJ; Evans AJ; Cornford EJ; Burrell HC; James JJ; Lee AH; Chakrabarti J
    AJR Am J Roentgenol; 2007 Mar; 188(3):676-83. PubMed ID: 17312053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparative value of mammographic screening for women 40-49 years old versus women 50-64 years old.
    Curpen BN; Sickles EA; Sollitto RA; Ominsky SH; Galvin HB; Frankel SD
    AJR Am J Roentgenol; 1995 May; 164(5):1099-103. PubMed ID: 7717212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-specific interval breast cancers in New South Wales and meta-analysis of studies of women aged 40-49 years.
    Taylor R; Page A; Bampton D; Estoesta J; Rickard M
    J Med Screen; 2004; 11(4):199-206. PubMed ID: 15563775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The National Breast and Cervical Cancer Early Detection Program: report on the first 4 years of mammography provided to medically underserved women.
    May DS; Lee NC; Nadel MR; Henson RM; Miller DS
    AJR Am J Roentgenol; 1998 Jan; 170(1):97-104. PubMed ID: 9423608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer.
    Wu JC; Hakama M; Anttila A; Yen AM; Malila N; Sarkeala T; Auvinen A; Chiu SY; Chen HH
    Breast Cancer Res Treat; 2010 Jul; 122(2):553-66. PubMed ID: 20054645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Contributions of the epidemiological cancer registries to the evaluation of mammography screening in Germany].
    Urbschat I; Kieschke J; Schlanstedt-Jahn U; von Gehlen S; Thiel A; Jensch P
    Gesundheitswesen; 2005 Jul; 67(7):448-54. PubMed ID: 16103967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of intermediate measures from a population-based, randomized trial of mammographic screening prevalence and detection of breast carcinoma among Asian women: the Singapore Breast Screening Project.
    Ng EH; Ng FC; Tan PH; Low SC; Chiang G; Tan KP; Seow A; Emmanuel S; Tan CH; Ho GH; Ng LT; Wilde CC
    Cancer; 1998 Apr; 82(8):1521-8. PubMed ID: 9554530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammography screening for breast cancer in Copenhagen April 1991-March 1997. Mammography Screening Evaluation Group.
    Lynge E
    APMIS Suppl; 1998; 83():1-44. PubMed ID: 9850674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening Mammography Program of British Columbia: pattern of use and health care system costs.
    Olivotto IA; Kan L; Mates D; King S
    CMAJ; 1999 Feb; 160(3):337-41. PubMed ID: 10065075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nationwide breast cancer screening fully accomplished; results from the implementation phase 1990-1997. National Evaluation Team for Breast Cancer Screening].
    Ned Tijdschr Geneeskd; 2000 Jun; 144(23):1124-9. PubMed ID: 10876708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diagnostic mode and tumor staging of breast cancers in the setting of opportunistic screenings].
    Graf O; Obermayer M; Scheurecker A; Hopf G; Kramer J; Frühwald F
    Rofo; 2006 Feb; 178(2):221-6. PubMed ID: 16435254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The British Columbia Mammography Screening Program: evaluation of the first 15 months.
    Burhenne LJ; Hislop TG; Burhenne HJ
    AJR Am J Roentgenol; 1992 Jan; 158(1):45-9. PubMed ID: 1307850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage distribution of breast cancer diagnosed before and after implementation of population-based mammographic screening.
    Hofvind S; Skaane P
    Rofo; 2012 May; 184(5):437-42. PubMed ID: 22426937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interval breast cancers: absolute and proportional incidence and blinded review in a community mammographic screening program.
    Carbonaro LA; Azzarone A; Paskeh BB; Brambilla G; Brunelli S; Calori A; Caumo F; Malerba P; Menicagli L; Sconfienza LM; Vadalà G; Brambilla G; Fantini L; Ciatto S; Sardanelli F
    Eur J Radiol; 2014 Feb; 83(2):e84-91. PubMed ID: 24369953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update of the Swedish two-county program of mammographic screening for breast cancer.
    Tabàr L; Fagerberg G; Duffy SW; Day NE; Gad A; Gröntoft O
    Radiol Clin North Am; 1992 Jan; 30(1):187-210. PubMed ID: 1732926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reviewing interval cancers: time well spent?
    Gower-Thomas K; Fielder HM; Branston L; Greening S; Beer H; Rogers C
    Clin Radiol; 2002 May; 57(5):384-8. PubMed ID: 12014936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer mortality after screening mammography in British Columbia women.
    Coldman A; Phillips N; Warren L; Kan L
    Int J Cancer; 2007 Mar; 120(5):1076-80. PubMed ID: 17149701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mammographic screening reduces risk of breast carcinoma recurrence.
    Immonen-Räihä P; Kauhava L; Parvinen I; Holli K; Kronqvist P; Pylkkänen L; Helenius H; Kaljonen A; Räsänen O; Klemi PJ
    Cancer; 2005 Feb; 103(3):474-82. PubMed ID: 15611974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study.
    Musolino A; Michiara M; Conti GM; Boggiani D; Zatelli M; Palleschi D; Bella MA; Sgargi P; Di Blasio B; Ardizzoni A
    J Clin Oncol; 2012 Jul; 30(19):2362-8. PubMed ID: 22585698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.